Eli Lilly and Viking Therapeutics both operate in the high-growth field of obesity drugs. This market is forecast to reach almost $100 billion by the end of the decade. The weight loss drug market is ...

Eli Lilly said it will spend $3.5 billion to build a manufacturing plant in Pennsylvania's Lehigh Valley that will help make its next-generation obesity drugs. That includes a closely watched ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. In early 2024, the Big Pharma debuted a pair of unbranded shorts entitled “Big ...

Eli Lilly & Co. struck a deal worth more than $1.1 billion with German biotech Seamless Therapeutics GmbH to develop gene therapies for hearing loss. Closely-held Seamless will design a type of enzyme ...

For Evangeline Lilly, the road to recovery doesn't have to be lonely. The Golden Globe-nominated actress, who has been navigating a traumatic brain injury, opened up about her recovery efforts in an ...

Eli Lilly is at the forefront of the GLP-1 weight loss drug market. The company's leading position is already being tested by Novo Nordisk's GLP-1 weight loss pill. Merck and Bristol Myers Squibb have ...

Evangeline Lilly is opening up about her costly treatment following a traumatic brain injury. “I have spent a lot of money getting evaluated and getting targeted, expert advice on how to heal my brain ...

Eli Lilly and Company's price jump following its latest earnings release is completely justified going by both the performance and guidance. Both LLY revenue and EPS growth exceeded guidance, despite ...

Evangeline Lily gave an update on her treatment plan after suffering a traumatic brain injury. The “Lost” star, 46, took to Instagram on Sunday, sharing how she was “restor[ing her] brain health.” “I ...

Eli Lilly and Co. has signed a deal worth up to $1.12 billion with Dresden, Germany-based-based Seamless Therapeutics to develop and commercialize treatments for hearing loss using the German ...

Eli Lilly plans to expand its hearing loss therapy pipeline by collaborating with Seamless Therapeutics to apply the company’s next-generation gene-editing approach, based on programmable recombinases ...